FEATURES OF THE COURSE OF PSEUDOMEMBRANOUS COLITIS IN PATIENTS INFECTED WITH SARS-COV-2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the context of the COVID-19 pandemic, intestinal lesions associated with this disease are a serious problem. Purpose: to analyze and identify the features of the course of pseudomembranous colitis in patients infected with SARS-CoV-2. Material and methods. The analysis was carried out on the basis of questionnaires, including information on the course and treatment of COVID-19, comorbidity, clinical symptoms of pseudomembranous colitis, results of colonoscopy, fecal ELISA for C. difficile toxins. Results and conclusion. 396 questionnaires of patients hospitalized with COVID-19 complicated by pseudomembranous colitis were analyzed. The maximum number of patients (36%) was recorded at the age of 60-69 years; women (65%) predominated in the structure of patients. The onset of symptoms of intestinal dyspepsia, in most cases (67%), was observed on the 10-20th day from the onset of COVID-19, and in 78,5% of cases, a recurrent course of colitis was observed. In 81% of cases, pseudomembranous colitis developed against the background of antibiotic therapy, and in 67% of cases, its development was combined with the appointment of proton pump inhibitors. Mortality from pseudomembranous colitis against the background of SARS-CoV-2 was very high (25,5%) and increased with increasing age of the patient, reaching a maximum (51,7%) in the group of patients over 80 years old. In 99%, the cause of deaths was the development of multiple organ failure against the background of concomitant pathology. Severe course of viral pneumonia in deceased patients was observed only in 17% of cases, which indicates the leading role of intestinal damage in the development of multiple organ failure syndrome in patients with pseudomembranous colitis against the background of infection with the SARS-CoV-2 virus.

Full Text

Restricted Access

About the authors

Elena Yu. Eremina

N.P. Ogarev National Research Mordovia State University

Email: eeu61@mail.ru
Dr med. habil., professor, head of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

Irina V. Gerasimenko

N.P. Ogarev National Research Mordovia State University

Email: gerasimenkoi@list.ru
PhD in Medicine, associate professor of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

Marina I. Lityushkina

N.P. Ogarev National Research Mordovia State University

Email: litjushkina@rambler.ru
PhD in Medicine, associate professor of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

Olga A. Strokova

N.P. Ogarev National Research Mordovia State University

Email: strokovaoa@rambler.ru
PhD in Medicine, associate professor of the Department of propaedeutics of internal diseases 430005, Saransk, 68 Bol'shevistskaya Str

References

  1. Guan W., Ni Z., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-20. https://dx.doi.org/.1056/NEJMoa2002032.
  2. Jin X., Lian J.-S., Hu J.-H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69(6): 1002-9. https://dx.doi.org/10.1136/gutjnl-2020-320926.
  3. Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115(5): 766-73. https://dx.doi.org/10.14309/ajg.0000000000000620.
  4. Zhou P., Yang X. L., Wang X. G. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020. https://dx.doi.org/10.1101/2020.01.22.914952.
  5. Hung I.F., Cheng V.C., Wu A.K. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004; 10(9): 1550-57. https://dx.doi.org/10.3201/eid1009.040058.
  6. Trottein F., Sokol H. Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection. Cell Rep. 2020; 32(3): 107915. https://dx.doi.org/10.1016/j.celrep.2020.107915.
  7. Matsumoto M., Kibe R., Ooga T. et al. Cerebral low-molecular metabolites influenced by intestinal microbiota: A pilot study. Front Syst Neurosci. 2013; 7: 9. https://dx.doi.org/10.3389/fnsys.2013.00009.
  8. Cryan J.F., Dinan T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012; 13(10): 701-12. https://dx.doi.org/10.1038/nrn3346.
  9. Macfarlane S., Dillon J.F. Microbial biofilms in the human gastrointestinal tract. J Appl Microbiol. 2007; 102(5): 1187-96. https://dx.doi.org/10.1111/j.1365-2672.2007.03287.x.
  10. Шульпекова Ю.О. Антибиотик-ассоциированная диарея. Русский медицинский журнал. 2007; 3: 467. [Shulpekova Yu.O. antibiotic associated diarrhea.Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2007; 3: 467 (In Russ.)].
  11. Koh A., de Vadder F., Kovatcheva-Datchary P., Backhed F. et al. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell. 2016; 165(6): 1332-45. https://dx.doi.org/10.1016/j.cell.2016.05.041.
  12. Kow C.S., Hasan S.S. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: A meta-analysis. J Intern Med. 2021; 289(1): 125-28. https://dx.doi.org/10.1111/joim.13183.
  13. Luxenburger H., Sturm L., Biever P. et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients withCOVID-19: Coincidence or underestimated risk factor? J Intern Med. 2021; 289(1): 121-24. https://dx.doi.org/10.1111/joim.13121.
  14. Еремина Е.Ю. Желудочно-кишечные симптомы у инфицированных SARS-CoV-2: акцент на повышенную проницаемость слизистой оболочки. Медицинский алфавит. 2021; 20: 13-20. [Eremina E.Yu. Gastrointestinal symptoms in SARSCoV 2 infected: emphasis on increased mucosal permeability. Meditsinskiy alfavit = Medical Alphabet. 2021; 20: 13-20 (In Russ.)]. https://dx.doi.org/10.33667/2078-5631-2021-20-13-20.
  15. Viana S.D., Nunes S., Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. Ageing Res Rev. 2020; 62: 101123. https://dx.doi.org/10.1016/j.arr.2020.101123.
  16. Jonsson A.L., Backhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017; 14(2): 79-87. https://dx.doi.org/10.1038/nrcardio.2016.183

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media